Trial reportEuropean journal of ophthalmology2023
Sodium hyaluronate 0.30% ocular gel versus sodium hyaluronate 0.18% eye drop in the treatment of moderate to severe dry eye disease.
Trial report in European journal of ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Safety and Effectiveness of Iota-Carrageenan Eye Drops for the Treatment of Dry Eye Disease.Clinical ophthalmology (Auckland, N.Z.) · 2026Trial
- A Prospective, Crossover, Randomized, Double-Blind Clinical Study Comparing the Effectiveness and Ocular Comfort of 0.1% Hyaluronic Acid and 0.3% Hyaluronic Acid in Patients With Dry Eye Disease.Clinical ophthalmology (Auckland, N.Z.) · 2025Trial
- Efficacy of 0.38% and 0.18% sodium hyaluronate ocular lubricants for dry eye: A randomized trial in adult gazan participants.Journal of optometryTrial
- Codelivering Polymyxin B and Phage Using Thermosensitive Hydrogel for Treating Carbapenem-ResistantACS omega · 2026Article
- Efficacy and Safety of 0.3% Preservative-Free Hyaluronic Acid-Based Eye Drops for the Management of Moderate to Severe Dry Eye Disease: A Prospective, Multicenter, Clinical Investigation.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- The Comparative Study of the Effects of Botulinum Toxin Micro-droplet Injection Combined with Micro-crosslinked Sodium Hyaluronate Gel or Focused Ultrasound Technology in Facial Rejuvenation Treatment.Aesthetic plastic surgery · 2025Article
- Overview of 37 Tear Substitutes in Europe Based on Various Physicochemical Parameters.Ophthalmology and therapy · 2024Article
- Different concentrations of hyaluronic acid eye drops for dry eye syndrome: a systematic review and Meta-analysis.International journal of ophthalmology · 2024Article
- Assessment of tear film parameters post-treatment with commercial eyelid cleaning wipes: a pilot study.International journal of ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCompare 0.30% sodium hyaluronate (0.30%HA) ocular gel with 0.18%HA eye drops in terms of improvement of ocular signs and symptoms, in patients with moderate to severe dry eye disease (DED).
methodsThis was a multicentric, randomized, investigator-masked, non-inferiority, comparative study conducted over 84 days. Three visits were scheduled, testing fluorescein corneal and conjunctival staining (Oxford and Van Bijsterveld scores), tear film break-up time (TBUT), Schirmer test, DED symptoms, 5-Item-Dry-Eye-Questionnaire (5-DEQ), patient and investigator satisfaction and frequency of instillation.
resultsAt Day 35 (D35) and Day 84 (D84), both groups (n = 35 each) had a significant improvement in corneal staining (p < 0.001) with no inter-group difference. Van Bijsterveld score improved earlier (D35) for 0.30%HA suggesting a faster effect on conjunctival epithelium healing. There was no difference between the two concentrations in terms of TBUT or Schirmer improvements; however, the Schirmer test increase was only significant for 0.30%HA at D35 (p = 0.040). At D35 and D84, both groups showed similar improvements of DED symptoms and DEQ-5 score. Furthermore, treatment satisfaction was similar for the 2 formulations suggesting that daily use of 0.30%HA do not cause gel-related blurred vision disturbances. Frequency of instillation was similar for both groups.
conclusionOur study demonstrates the non-inferiority of 0.30%HA gel compared to 0.18%HA solution in patients with moderate to severe DED. Because of its gel formulation and higher HA concentration providing prolonged comfort without causing visual disturbances, 0.30%HA gel might be adapted for bedtime use or during the day in more severe conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.